Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study
- PMID: 37186260
- DOI: 10.1210/clinem/dgad235
Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study
Abstract
Context: The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism.
Methods: This nationwide, multicenter, retrospective cohort study included 53 endocrinology centers in Turkey. The study participants were divided into either COVID-19-related SAT (Cov-SAT), SARS-CoV-2 vaccine-related SAT (Vac-SAT), or control SAT (Cont-SAT) groups.
Results: Of the 811 patients, 258 (31.8%) were included in the Vac-SAT group, 98 (12.1%) in the Cov-SAT group, and 455 (56.1%) in the Cont-SAT group. No difference was found between the groups with regard to laboratory and imaging findings. SAT etiology was not an independent predictor of recurrence or hypothyroidism. In the entire cohort, steroid therapy requirement and younger age were statistically significant predictors for SAT recurrence. C-reactive protein measured during SAT onset, female sex, absence of antithyroid peroxidase (TPO) positivity, and absence of steroid therapy were statistically significant predictors of incident (early) hypothyroidism, irrespective of SAT etiology. On the other hand, probable predictors of established hypothyroidism differed from that of incident hypothyroidism.
Conclusion: Since there is no difference in terms of follow-up parameters and outcomes, COVID-19- and SARS-CoV-2 vaccine-related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.
Keywords: COVID-19; SARS-CoV-2 vaccine; subacute thyroiditis.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Subacute thyroiditis during the COVID-19 pandemic: a prospective study.J Endocrinol Invest. 2022 Apr;45(4):865-874. doi: 10.1007/s40618-021-01718-x. Epub 2022 Jan 13. J Endocrinol Invest. 2022. PMID: 35023078 Free PMC article.
-
Letter to the Editor From Kleebayoon and Wiuwanikit: "Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study".J Clin Endocrinol Metab. 2023 Dec 21;109(1):e432. doi: 10.1210/clinem/dgad428. J Clin Endocrinol Metab. 2023. PMID: 37463482 No abstract available.
-
Response to Letter to the Editor From Kleebayoon and Wiuwanikit: "Subacute THYROiditis Related to SARS-CoV-2 Vaccine and COVID-19 (THYROVAC Study): A Multicenter Nationwide Study".J Clin Endocrinol Metab. 2023 Dec 21;109(1):e436. doi: 10.1210/clinem/dgad462. J Clin Endocrinol Metab. 2023. PMID: 37554094 No abstract available.
-
Subacute Thyroiditis Following SARS-CoV-2 Vaccines: Six Cases Report and Review of the Literature.Horm Metab Res. 2022 Aug;54(8):556-561. doi: 10.1055/a-1804-9561. Epub 2022 Mar 22. Horm Metab Res. 2022. PMID: 35318621 Review.
-
Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review.Intern Med J. 2022 Apr;52(4):522-529. doi: 10.1111/imj.15432. Intern Med J. 2022. PMID: 34139048 Free PMC article. Review.
Cited by
-
SARS-CoV-2-Vaccine-Related Endocrine Disorders: An Updated Narrative Review.Vaccines (Basel). 2024 Jul 8;12(7):750. doi: 10.3390/vaccines12070750. Vaccines (Basel). 2024. PMID: 39066388 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous